Keros Therapeutics director plans 575-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Keros Therapeutics, Inc. (KROS) director Anne Prener reported a planned sale of 575 common shares, with an approximate sale date of November 17, 2026, and an aggregate market value of $5,761.50. The plan adoption or instruction date associated with Rule 10b5-1 reliance is August 6, 2026. Anne Prener also reported selling 574 shares on November 12, 2026, for gross proceeds of $5,619.46.
Key Figures
Key Terms
RSU Vesting financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.